Press Release April 16, 2019

insitro Strikes AI Drug Discovery Deal with Gilead for NASH, with up to $50 million in Near-Term Payments and $1 Billion in Deal Value

The Life Sciences team advised insitro on its strategic collaboration with Gilead Sciences Inc. (Nasdaq: GILD) to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH). Under the terms of the collaboration, insitro’s proprietary platform will be utilized to create disease models for NASH and discover targets that have an influence on clinical progression and regression of the disease.

insitro will receive an upfront payment of $15 million, with additional near-term payments up to $35 million based on operational milestones. insitro will be eligible to receive up to $200 million for the achievement of preclinical, development, regulatory and commercial milestones for each of the five Gilead targets; and up to low double-digit tiered royalties on net sales. For programs where insitro opts in, it will have the right to co-develop and co-detail in the U.S., receive a profit share in China and receive milestone payments and royalties on other ex-U.S. sales.

insitro is a data-driven drug discovery and development company that uses machine learning to transform the way that drugs are discovered and delivered to patients. By generating high-throughput, functional genomic data sets that align with patient data, and interpreting those data via novel machine learning methods, insitro builds predictive models that can accelerate target selection and the design of effective therapeutics.

The Goodwin team was led by partner Kingsley Taft and associate Erini Svokos. Partner Michael Shuster led the patent-related elements of the transaction.

For additional details on the collaboration, please read the press release.